Welcome to our dedicated page for Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares stock.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) is at the forefront of developing innovative respiratory support technology as an alternative to invasive mechanical ventilation. The company's flagship product, INSPIRA ART100, is a breakthrough in Augmented Respiration Technology designed to maintain optimal oxygen levels in patients without the need for intubation and sedation. This technology is particularly significant in the treatment of respiratory failure and offers a less invasive option compared to traditional mechanical ventilation.
Inspira Technologies operates in various regions, including North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The company is involved in the research, development, manufacture, and marketing of proprietary respiratory care devices, aiming to transform the landscape of acute and neonatal care.
Recently, Inspira Technologies has announced several key developments:
- April 3, 2024: Commencement of a program to explore the use of the INSPIRA ART100 Device for an artificial womb for neonates requiring vital respiratory support.
- April 10, 2024: Collaborative development with Ennocure MedTech Ltd. on bio-electronic treatment to prevent bloodstream infections in ICU patients, showcasing a 100% reduction in bacterial growth within 24 hours in an in vitro study.
- April 16, 2024: Signing of a collaboration term sheet with Beilinson Hospital for the evaluation of the INSPIRA ART100 device in organ transplant procedures.
- April 25, 2024: Receiving CSA Certification of Compliance to U.S. standards for the INSPIRA ART100 device.
- May 2, 2024: Initiation of the production of the INSPIRA ART100 medical device by a leading technology company.
- May 28, 2024: Notification of 510(k) class II clearance from the U.S. FDA for the INSPIRA ART100.
Inspira's products are designed not only to enhance patient outcomes but also to reduce the costs and complications associated with traditional respiratory support methods. The INSPIRA ART100 system has received FDA clearance, marking a pivotal moment in the company's history. Other products in the pipeline, including the INSPIRA ART (Gen 2) and HYLA™ blood sensor, are poised to further revolutionize respiratory care once approved.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has unveiled the Liby™ System, a new extracorporeal membrane oxygenation (ECMO) device designed to treat severe heart and lung failure. Targeting a $531 million global ECMO market, the system is set for FDA submission in H1 2023 and may qualify as a Class II 510(k) device, potentially bypassing human trials. The Liby™ system aims to enhance patient mobility and usability in ICUs, generating recurring revenue through disposable kits, similar to its ART™ system.
Inspira Technologies has signed a strategic agreement with Glo-Med Networks for the potential distribution of the HYLA™ Blood Sensors across six US states over three years, pending regulatory approvals. This contract includes a minimum purchase commitment of 3,889 sensors and 264,873 disposable units, potentially worth $59 million. This agreement follows a previous contract for the ART™ system and positions Inspira for significant growth in the medical device market.
Inspira Technologies (NASDAQ: IINN) announced the development of the non-invasive HYLA™ blood sensor, aiming to transform patient monitoring by providing continuous, real-time blood analysis without drawing blood. Targeting a potential $2.5 billion market, the sensor's applications include critical care settings and various medical procedures. Designed using machine learning, it can measure key health indicators like oxygen and carbon dioxide levels. The technology is still in development and requires regulatory approval.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, NASDAQ:IINNW) will be featured on The RedChip Money Report airing on Bloomberg TV on July 2, 2022, at 7 p.m. ET. CEO Dave Gentry interviews CFO Joe Hayon, discussing the Company’s Augmented Respiration Technology (ART), which aims to enhance respiratory support for acute respiratory failure patients. The technology seeks to minimize the need for invasive ventilation methods. Inspira targets $401 million in potential sales through its ongoing agreements and is actively pursuing regulatory approval in the U.S. and Europe.
Inspira Technologies (Nasdaq: IINN) reported its Q1 2022 financial results, announcing a net loss of $1.3 million, significantly down from $7.2 million in Q1 2021. The company had $21.7 million in cash as of March 31, 2022. R&D expenses rose to $1.5 million, driven by hiring specialized staff. Marketing and general administrative expenses also increased to $472,000 and $1.5 million, respectively. Inspira is focused on FDA submissions for its ART system and has secured strategic agreements potentially worth $212 million over seven years.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has announced its participation in several key events in May 2022, showcasing its innovative respiratory support technology. Highlights include the Medtech Forum in Barcelona from May 3-5, featuring VP Adi Rizansky Nir, and the EuroELSO Congress in London from May 4-6, with CTO Daniella Yeheskely-Hayon. The company will also present at the Sidoti Virtual Microcap Conference on May 11 and engage in a Fireside Chat at the Benzinga Virtual All Access Show on May 20, led by CFO Joe Hayon.
The company’s ART device aims to support respiratory patients efficiently.
Inspira Technologies announced a summary distribution agreement with Bepex Ltd. aimed at deploying its Augmented Respiration Technology (ART) systems in Israel's medical centers. This partnership follows three prior agreements collectively targeting approximately $386M in the U.S. and European markets, pending regulatory approvals. The initial term of the agreement is set for seven years. The ART system is projected to provide innovative care for acute respiratory failure, potentially reducing reliance on invasive mechanical ventilation.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has published its financial results for 2021, available on its Investor Relations website. The report outlines key metrics and insights from the company's operations over the past year. For a detailed overview, stakeholders are encouraged to view the CEO update linked in the announcement.
Inspira Technologies has been awarded the 2021 Europe Technology Innovation Leadership Award by Frost & Sullivan for its ART system, a novel respiratory support technology. Designed to be a second-line treatment, the ART minimizes the need for invasive mechanical ventilation (MV) by optimizing oxygen saturation while patients are awake. The ART system uses a low-flow approach, reducing health risks associated with traditional methods like ECMO. The company plans to submit a FDA filing for the ART system in H2-2023, marking significant strides in the respiratory care market.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has received the 2021 Europe Technology Innovation Leadership Award in the artificial respiratory market from Frost & Sullivan. This recognition highlights the innovative ART™ system, which aims to reduce the reliance on invasive mechanical ventilation. Frost & Sullivan praised ART for its plug-and-play simplicity and its potential to improve patient care by minimizing lung damage. Despite this progress, the ART system has not yet been approved by the FDA or other regulatory bodies, leaving its market viability uncertain.
FAQ
What is the current stock price of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN)?
What is the market cap of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN)?
What does Inspira Technologies do?
What is the INSPIRA ART100?
What regions does Inspira Technologies operate in?
What recent programs has Inspira Technologies announced?
Who are some of Inspira Technologies' partners?
Has the INSPIRA ART100 received regulatory approval?
What makes the INSPIRA ART100 different from traditional mechanical ventilation?
What is the significance of the CSA Certification of Compliance?
What is the financial impact of mechanical ventilation in the U.S.?
Where can I find more information about Inspira Technologies?
